PDF(Pubmed)
Abstract：
OBJECTIVE: Brachytherapy has been indicated as an alternative option for treating cystic craniopharyngiomas (CPs). The potential benefits of brachytherapy for CPs have not yet been clarified. The purpose of this work was to conduct a meta-analysis to analyze the long-term efficacy and adverse reactions profile of brachytherapy for CPs.
METHODS: The relevant databases were searched to collect the clinical trials on brachytherapy in patients with CPs. Included studies were limited to publications in full manuscript form with at least 5-year median follow-up, and adequate reporting of treatment outcomes and adverse reactions data. Stata 12.0 was used for data analysis.
RESULTS: According to the inclusion and exclusion criteria, a total of 6 clinical trials involving 266 patients with CPs were included in this meta-analysis. The minimum average follow-up was 5 years. The results of the meta-analysis showed that 1-year, 2-3 years and 5 years progression free survival rates (PFS) are 75% (95%CI: 66-84%), 62% (95%CI: 52-72%) and 57% (95%CI: 22-92%), respectively. At the last follow-up, less than 16% of patients with visual outcomes worser than baseline in all included studies. While, for endocrine outcomes, less than 32% of patients worser than baseline level.
CONCLUSIONS: In general, based on the above results, brachytherapy should be considered as a good choice for the treatment of CP.
METHODS: The relevant databases were searched to collect the clinical trials on brachytherapy in patients with CPs. Included studies were limited to publications in full manuscript form with at least 5-year median follow-up, and adequate reporting of treatment outcomes and adverse reactions data. Stata 12.0 was used for data analysis.
RESULTS: According to the inclusion and exclusion criteria, a total of 6 clinical trials involving 266 patients with CPs were included in this meta-analysis. The minimum average follow-up was 5 years. The results of the meta-analysis showed that 1-year, 2-3 years and 5 years progression free survival rates (PFS) are 75% (95%CI: 66-84%), 62% (95%CI: 52-72%) and 57% (95%CI: 22-92%), respectively. At the last follow-up, less than 16% of patients with visual outcomes worser than baseline in all included studies. While, for endocrine outcomes, less than 32% of patients worser than baseline level.
CONCLUSIONS: In general, based on the above results, brachytherapy should be considered as a good choice for the treatment of CP.
摘要：
目的：近距离放射治疗已被认为是治疗囊性颅咽管瘤（CPs）的替代选择。近距离放射治疗对CP的潜在益处尚未得到澄清。这项工作的目的是进行荟萃分析，以分析近距离放射疗法对CPs的长期疗效和不良反应。
方法：检索相关数据库以收集CPs患者近距离放射治疗的临床试验。纳入的研究仅限于完整手稿形式的出版物，至少有5年的中位随访时间。并充分报告治疗结果和不良反应数据。Stata12.0用于数据分析。
结果：根据纳入和排除标准，本荟萃分析共纳入6项临床试验,涉及266例CPs患者.最低平均随访时间为5年。荟萃分析的结果表明，1年，2-3年和5年无进展生存率（PFS）为75％（95CI：66-84％），62%（95CI：52-72%）和57%（95CI：22-92%），分别。在最后一次随访中，在所有纳入研究中,视力结局比基线差的患者中,少于16%.同时,对于内分泌结果，少于32%的患者比基线水平恶化。
结论：一般来说，基于上述结果，近距离放射治疗应被视为治疗CP的良好选择.
方法：检索相关数据库以收集CPs患者近距离放射治疗的临床试验。纳入的研究仅限于完整手稿形式的出版物，至少有5年的中位随访时间。并充分报告治疗结果和不良反应数据。Stata12.0用于数据分析。
结果：根据纳入和排除标准，本荟萃分析共纳入6项临床试验,涉及266例CPs患者.最低平均随访时间为5年。荟萃分析的结果表明，1年，2-3年和5年无进展生存率（PFS）为75％（95CI：66-84％），62%（95CI：52-72%）和57%（95CI：22-92%），分别。在最后一次随访中，在所有纳入研究中,视力结局比基线差的患者中,少于16%.同时,对于内分泌结果，少于32%的患者比基线水平恶化。
结论：一般来说，基于上述结果，近距离放射治疗应被视为治疗CP的良好选择.
